28 completed, 12 terminated, 11 recruiting, 11 unknown. 71 Phase 3, 11 Phase 2.
Follow Mitomycin: new trials by email Literature Review of Mitomycin trials Research Report on Mitomycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC SHR-1501 for Injection, BCG for Injection, Epirubicin Hydrochloride for Injection - NMIBC | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 236 | 2026-07-13 | 2026-07-20 |
| Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer Mitomycin (MM), FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Cytoreductive surgery - Locally Advanced Colorectal Cancer | Phase 3 | Recruiting | Maimónides Biomedical Research Institute of Córdoba | 1083 | 2026-05-26 | 2026-06-08 |
| Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy - Urothelial Cancer, Urinary Bladder Neoplasms | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 390 | 2026-05-11 | 2026-10-28 |
| Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma Intensity-Modulated Radiotherapy (IMRT), Capecitabine, Sintilimab - Anal Squamous Cell Carcinoma, Limited-stage | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 350 | 2026-03-17 | 2026-07-09 |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study Biospecimen Collection, Cisplatin, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 486 | 2025-10-07 | 2026-10-23 |
| A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer TAR-210, Mitomycin C, Gemcitabine - Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 220 | 2025-09-10 | 2026-09-28 |
| A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer UGN-104 - Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma | Phase 3 | Recruiting | UroGen Pharma Ltd. | 70 | 2025-08-06 | 2026-09-03 |
| Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients Mitomycin C (MMC), Normal Saline (Placebo) - Non-Muscle-Invasive Bladder Cancer (NMIBC) | Phase 3 | Recruiting | Shaogang Wang | 180 | 2025-02-17 | 2025-02-19 |
| Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP) Mitomycin c - Pseudomyxoma Peritonei | Phase 3 | Recruiting | University of Southampton | 176 | 2024-12-04 | 2026-02-19 |
| Effect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation Surgery Mitomycin c - Glaucoma | Phase 3 | Not yet recruiting | St. Joseph's Healthcare Hamilton | 144 | 2024-12-01 | 2024-11-08 |
| A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer UGN-103 - Bladder Cancer, Urothelial Carcinoma | Phase 3 | Completed | UroGen Pharma Ltd. | 99 | 2024-08-29 | 2026-10-22 |
| A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) TAR-200, Mitomycin C, Gemcitabine - Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 272 | 2024-04-09 | 2026-09-25 |
| Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA induction chemotherapy (mDCF), Concomitant chemotherapy (Capecitabin + Mitomycin-C), radiotherapy - Anal Cancer | Phase 3 | Recruiting | Federation Francophone de Cancerologie Digestive | 310 | 2024-02-26 | 2025-09-02 |
| REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation Radiation (reduced elective nodal dose (30.6 Gy), Capecitabine, Mitomycin c - Anal Cancer | Phase 2 / Phase 3 | Active not recruiting | University of Cincinnati | 33 | 2023-08-14 | 2025-12-18 |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer UGN-102 - Bladder Cancer, Urothelial Carcinoma | Phase 3 | Active not recruiting | UroGen Pharma Ltd. | 240 | 2022-03-01 | 2026-05-11 |
| Intralesional Injection of Mitomycin C Following Visual Internal Urethrotomy for Recurrent Urethral Stricture Mitomycin c - Urethral Stricture | Phase 2 / Phase 3 | Completed | Ain Shams University | 50 | 2022-01-01 | 2024-01-30 |
| Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) UGN-102 - Bladder Cancer, Urothelial Carcinoma | Phase 3 | Completed | UroGen Pharma Ltd. | 8 | 2021-11-30 | 2024-09-19 |
| A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer UGN-102, TURBT - Bladder Cancer, Urothelial Carcinoma | Phase 3 | Terminated | UroGen Pharma Ltd. | 282 | 2021-02-19 | 2024-06-06 |
| BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer Bacillus Calmette-Guerin Vaccine Intravesical, Mitomycin - Transitional Cell Carcinoma, Transurethral Resection | Phase 3 | Active not recruiting | Nottingham University Hospitals NHS Trust | 500 | 2020-12-10 | 2024-06-17 |
Showing 20 of 71. Sign in to see all of them.
Urinary Bladder Neoplasms (19) · Non-Muscle Invasive Bladder Neoplasms (13) · Carcinoma, Transitional Cell (12) · Anus Neoplasms (8) · Colorectal Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Glaucoma (5) · Lung Neoplasms (4) · Neoplasms (4) · Carcinoma (3) · Carcinoma, Hepatocellular (3) · Anal Canal Carcinoma (2) · Carcinoma in Situ (2) · Colonic Neoplasms (2) · Neoplasms by Site (2)
UroGen Pharma Ltd. (7) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Medical Research Council (3) · National Cancer Institute (NCI) (3) · University of Rome Tor Vergata (3) · Asan Medical Center (2) · Janssen Research & Development, LLC (2) · Maimónides Biomedical Research Institute of Córdoba (2) · University Hospital Birmingham (2) · Abnoba Gmbh (1) · Ain Shams University (1) · Aktion Bronchialkarzinom e.V. (1) · Albert Koong (1) · Alliance for Clinical Trials in Oncology (1) · American College of Radiology Imaging Network (1)
United States (29) · United Kingdom (18) · Italy (8) · Spain (8) · Germany (7) · South Korea (7) · China (6) · Israel (6) · Poland (6) · France (5) · Latvia (5) · Netherlands (5) · Belgium (4) · Bulgaria (4) · Estonia (4)
Savino M Di Stasi, MD, PhD (3) · Ian E. Smith, MD (2) · Sandip Prasad, MD (2) · Yoon-Koo Kang, M.D.,Ph.D. (2) · Adrian Hodson (1) · Al B Benson (1) · Al B. Benson, MD, FACP (1) · Albert Koong (1) · Alex W Yeung, MBBS (1) · Alexander Stojadinovic, MD (1) · Arsen O Rasulov, PhD (1) · Brian R Lane, MD (1) · Chia-Jui Yen Yen, MD. PhD (1) · Ching-Yun Hsieh, MD (1)
PMID 10937547, PMID 16157935, PMID 16389183, PMID 17122118, PMID 17544497, PMID 18430910, PMID 18486741, PMID 19139424, PMID 19643599, PMID 20564111, PMID 21831711, PMID 22512481, PMID 23150707, PMID 25019269, PMID 25954110, PMID 29439668, PMID 30247524, PMID 30274699, PMID 30390114, PMID 31785830, PMID 32631491, PMID 32670424, PMID 33539743, PMID 33677615, PMID 34125951, PMID 36912740, PMID 37012180, PMID 37099280, PMID 37548555, PMID 39446087, PMID 39561384, PMID 40048558, PMID 41880645, PMID 41891861
2023 (3), 2019 (1), 2025 (1), P30CA033572 (1), U01CA079778 (1), U01CA080098 (1), U10CA021115 (1), U10CA180820 (1), U10CA180868 (1), U10CA180888 (1)